Cybin Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Doug Drysdale

Directeur général

CA$2.1m

Rémunération totale

Pourcentage du salaire du PDG	32.6%
Durée du mandat du directeur général	4yrs
Propriété du PDG	0.02%
Durée moyenne d'occupation des postes de direction	4yrs
Durée moyenne du mandat des membres du conseil d'administration	4yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Doug Drysdale a-t-elle évolué par rapport aux bénéfices de Cybin?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-CA$124m
Jun 30 2024	n/a	n/a	-CA$78m
Mar 31 2024	CA$2m	CA$681k	-CA$78m
Dec 31 2023	n/a	n/a	-CA$70m
Sep 30 2023	n/a	n/a	-CA$51m
Jun 30 2023	n/a	n/a	-CA$49m
Mar 31 2023	CA$804k	CA$680k	-CA$47m
Dec 31 2022	n/a	n/a	-CA$52m
Sep 30 2022	n/a	n/a	-CA$58m
Jun 30 2022	n/a	n/a	-CA$66m
Mar 31 2022	CA$3m	CA$549k	-CA$68m
Dec 31 2021	n/a	n/a	-CA$63m
Sep 30 2021	n/a	n/a	-CA$58m
Jun 30 2021	n/a	n/a	-CA$43m
Mar 31 2021	CA$2m	CA$277k	-CA$32m

Rémunération vs marché: La rémunération totale de Doug ($USD 1.49M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Canadian ($USD 708.78K ).

Rémunération et revenus: La rémunération de Doug a augmenté alors que l'entreprise n'est pas rentable.

PDG

Doug Drysdale (54 yo)

4yrs

Titularisation

CA$2,092,583

Compensation

Mr. Douglas L. Drysdale, also known as Doug, is Chief Executive Officer at Cybin, Inc. since November 05, 2020. Mr. Drysdale serves as the Member of Board of Directors for SpineThera, Inc. from May 2022. H...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Eric So	Co-Founder	4yrs	CA$3.36m	1.56% CA$ 4.7m
Douglas Drysdale	Chief Executive Officer	4yrs	CA$2.09m	0.021% CA$ 62.2k
Paul Glavine	Co-Founder	no data	CA$3.36m	1.5% CA$ 4.5m
Greg Cavers	Chief Financial Officer	4yrs	CA$880.42k	0.013% CA$ 39.4k
Aaron Bartlone	Chief Operating Officer	1.3yrs	CA$1.03m	0.12% CA$ 354.9k
George Tziras	Chief Business Officer & Director	1.1yrs	CA$310.55k	0.17% CA$ 510.0k
John Kanakis	Co-Founder	no data	CA$1.49m	pas de données
Alex Nivorozhkin	Chief Scientific Officer	3.9yrs	pas de données	0% CA$ 0
Lori Challenger	Chief Compliance	3.1yrs	pas de données	pas de données
Gabriel Fahel	Chief Legal Officer & Corporate Secretary	4yrs	pas de données	0.053% CA$ 158.8k
Sara Somerset	Chief Communications Officers	no data	pas de données	pas de données
James Andrews	Chief Cultivation & Extraction Officer	no data	pas de données	pas de données

4.0yrs

Durée moyenne de l'emploi

48yo

Âge moyen

Gestion expérimentée: L'équipe de direction de CYBN est considérée comme expérimentée (ancienneté moyenne 4 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Eric So	Co-Founder	4yrs	CA$3.36m	1.56% CA$ 4.7m
Paul Glavine	Co-Founder	4yrs	CA$3.36m	1.5% CA$ 4.5m
George Tziras	Chief Business Officer & Director	1.1yrs	CA$310.55k	0.17% CA$ 510.0k
Theresa Firestone	Lead Independent Director	3.3yrs	CA$304.80k	0.0053% CA$ 15.8k
Mark Lawson	Independent Director	4yrs	CA$291.56k	0.015% CA$ 45.3k
Grant Froese	Independent Director	4yrs	CA$289.80k	0.026% CA$ 78.8k
Eric Hoskins	Independent Director	4yrs	CA$289.80k	0.013% CA$ 39.4k

4.0yrs

Durée moyenne de l'emploi

51yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de CYBN sont considérés comme expérimentés (ancienneté moyenne 4 ans).

Cybin Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Cybin Inc. Announces Executive Appointments

Insufficient new directors

Cybin Inc. Announces the Realignment of the Composition of Governance and Nominating Committee, and Compensation Committee

Cybin Inc., Annual General Meeting, Aug 27, 2024

Co-Founder recently bought CA$87k worth of stock

Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development

Recent updates

New major risk - Shareholder dilution

Cybin Reports Positive Phase 2 Data for Cyb003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

New minor risk - Profitability

No longer forecast to breakeven

Cybin Initiates PARADIGM Multinational Pivotal Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Cybin Inc. Announces Executive Appointments

Cybin Inc. Provides Corporate Update on Upcoming Clinical Milestones

Insufficient new directors

Forecast to breakeven in 2027

Cybin Inc. Announces the Realignment of the Composition of Governance and Nominating Committee, and Compensation Committee

Cybin Inc., Annual General Meeting, Aug 27, 2024

Co-Founder recently bought CA$87k worth of stock

No longer forecast to breakeven

Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development

Forecast to breakeven in 2027

New minor risk - Share price stability

Cybin Inc. announced that it has received $150 million in funding from a group of investors

New minor risk - Profitability

Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder

Cybin Inc. Receives FDA Breakthrough Therapy Designation for Its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

Cybin Inc. announced that it expects to receive $150 million in funding from a group of investors

Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder

Cybin Inc. Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028

Cybin Inc. Announces the Presentation of Four Posters At the American College of Neuropsychopharmacology Annual Meeting

Cybin Inc. Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses

Cybin Inc. has completed a Composite Units Offering in the amount of $30 million.

New major risk - Revenue and earnings growth

Cybin Inc. Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose

Cybin Inc. completed the acquisition of Small Pharma Inc. (TSXV : DMT).

New major risk - Shareholder dilution

Cybin Inc. Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder

Cybin Inc. agreed to acquire Small Pharma Inc. (TSXV : DMT) for $23.2 million.

Cybin Inc. Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial

New major risk - Financial position

Cybin Inc. has completed a Composite Units Offering in the amount of $8.25 million.

Cybin Inc. Announces Phase 2 Cohort 5 Dosing Completion of Cyb003 in Major Depressive Disorder

Cybin Inc. Announces Publication of Sponsored Feasibility Study Validating Kernel's Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain

Cybin Inc. Announces the Development of Scalable Psychedelic Facilitation Training Program, Embarkct

New minor risk - Share price stability

Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer, Effective July 1, 2023

Cybin Inc., Annual General Meeting, Aug 29, 2023

Cybin Announces Scientific Management Transition

Cybin Inc. announced that it expects to receive CAD 41 million in funding from Lincoln Park Capital, LLC

Cybin Inc. Initiates First-In-Human Dosing of CYB004 in Phase 1 Clinical Trial

Cybin Inc. Announces Last Subject Dosed in Part B of Its Phase 1 CYB004-E Trial

Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004

Cybin Inc. Announces Promising Results from Sponsored Kernel Flow Feasibility Study Measuring Psychedelic Effects on the Brain

Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004

Cybin Inc. Outlines Upcoming Priorities and Milestones for Its Clinical Development Programs

High number of new and inexperienced directors

Cybin Inc. Provides Progress Update on Its Cyb004-E Phase 1 Trial

Cybin Achieves Research and Development Milestones Ahead of Projected Timelines

Cybin Inc. Announces First Participants Dosed in Its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder

Cybin Inc. and Clinilabs Drug Development Corporation Announces U.S. Drug Enforcement Agency Grant A Schedule I License to Support the First-In-Human Phase 1/2A Clinical Trial of CYB003

Cybin Inc. Announces Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2A Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

Independent Director recently bought CA$73k worth of stock

Cybin Inc. Receives Fda Ind Clearance for Its Phase 1/2A Clinical Trial Evaluating Cyb003 for the Potential Treatment of Major Depressive Disorder

Cybin Inc., Annual General Meeting, Aug 15, 2022

Cybin Receives Institutional Review Board Approval for Its Phase 1/2A Clinical Trial Evaluating Cyb003 for the Treatment of Major Depressive Disorder

Cybin Acquires DMT Clinical Study from Entheon Biomedical

Cybin Inc. Submits IND Application to FDA for its Phase 1/2a First-In-Human Trial of CYB003 for Treatment of Major Depressive Disorder

Cybin and Kernel Announce Results from Kernel Flow Piloting of Feasibility Study Measuring Ketamine's Effects on the Brain

Cybin Inc. Announces CYB003 Poster to be Presented at the ‘From Research to Reality’ Global Summit on Psychedelic-Assisted Therapies and Medicine

High number of new and inexperienced directors

Cybin Inc. Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT

Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

High number of new and inexperienced directors

Cybin Announces Successful Completion of in Vivo Preclinical Studies for Its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial